Loading
HKSEHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
HK$1.96
−HK$0.025 · -1.26%
Golden Throat Holdings Group Company Limited operates as an investment holding entity primarily engaged in the production and distribution of pharmaceutical goods, health-focused foods, and various other products within the People's Republic of China. Among its offerings are the widely recognized Golden Throat lozenges, an over-the-counter remedy designed to alleviate discomfort from sore and dry throats, as well as hoarseness often stemming from acute pharyngitis. The company further expands its Golden Throat lozenge line with products like Dule lozenges and their sugar-free counterparts, available in diverse flavors including orange, fructus momordicae, chrysanthemum, American ginseng, and hawthorn. Additionally, Golden Throat manufactures the Yinxingye tablet, formulated to enhance blood circulation, disperse blood stasis, and clear energy pathways. Its product portfolio also encompasses herbal vegetable beverages, crafted to provide vocal comfort and soothe irritated throats. Beyond its domestic market, the company extends its reach globally, exporting its range of products to countries and regions such as the United States, Canada, Russia, the European Union, Australia, Southeast Asia, the Middle East, Mexico, and across Africa. Established in 1956, Golden Throat Holdings Group Company Limited maintains its corporate headquarters in Liuzhou, within the People's Republic of China.
Latest quote
HK$1.96
−HK$0.025 · -1.26%
Regular session · HKT · Market data may be delayed.
Golden Throat Holdings Group Company Limited operates as an investment holding entity primarily engaged in the production and distribution of pharmaceutical goods, health-focused foods, and various other products within the People's Republic of China. Among its offerings are the widely recognized Golden Throat lozenges, an over-the-counter remedy designed to alleviate discomfort from sore and dry throats, as well as hoarseness often stemming from acute pharyngitis. The company further expands its Golden Throat lozenge line with products like Dule lozenges and their sugar-free counterparts, available in diverse flavors including orange, fructus momordicae, chrysanthemum, American ginseng, and hawthorn. Additionally, Golden Throat manufactures the Yinxingye tablet, formulated to enhance blood circulation, disperse blood stasis, and clear energy pathways. Its product portfolio also encompasses herbal vegetable beverages, crafted to provide vocal comfort and soothe irritated throats. Beyond its domestic market, the company extends its reach globally, exporting its range of products to countries and regions such as the United States, Canada, Russia, the European Union, Australia, Southeast Asia, the Middle East, Mexico, and across Africa. Established in 1956, Golden Throat Holdings Group Company Limited maintains its corporate headquarters in Liuzhou, within the People's Republic of China.
Day range
Current HK$1.96
52-week range
Current HK$1.96
Regular session · HKT · Market data may be delayed.
Golden Throat Holdings Group Company Limited operates as an investment holding entity primarily engaged in the production and distribution of pharmaceutical goods, health-focused foods, and various other products within the People's Republic of China. Among its offerings are the widely recognized Golden Throat lozenges, an over-the-counter remedy designed to alleviate discomfort from sore and dry throats, as well as hoarseness often stemming from acute pharyngitis. The company further expands its Golden Throat lozenge line with products like Dule lozenges and their sugar-free counterparts, available in diverse flavors including orange, fructus momordicae, chrysanthemum, American ginseng, and hawthorn. Additionally, Golden Throat manufactures the Yinxingye tablet, formulated to enhance blood circulation, disperse blood stasis, and clear energy pathways. Its product portfolio also encompasses herbal vegetable beverages, crafted to provide vocal comfort and soothe irritated throats. Beyond its domestic market, the company extends its reach globally, exporting its range of products to countries and regions such as the United States, Canada, Russia, the European Union, Australia, Southeast Asia, the Middle East, Mexico, and across Africa. Established in 1956, Golden Throat Holdings Group Company Limited maintains its corporate headquarters in Liuzhou, within the People's Republic of China.
Day range
Current HK$1.96
52-week range
Current HK$1.96
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 943.26M CNY | 1.19B CNY | 961.38M CNY | 992.01M CNY | 820.54M CNY |
| Cost of goods sold | 226.25M CNY | 290.82M CNY | 263.66M CNY | 271.09M CNY | 242.81M CNY |
| Gross profit | 717.01M CNY | 894.18M CNY | 697.72M CNY | 720.92M CNY | 577.74M CNY |
| Research and development | 3.93M CNY | 32.42M CNY | 17.07M CNY | 6.42M CNY | 22.29M CNY |
| Selling, general, and administrative | 410.3M CNY | 473.04M CNY | 360.98M CNY | 357.6M CNY | 364.79M CNY |
| Operating expenses | 414.22M CNY | 505.46M CNY | 378.05M CNY | 364.02M CNY | 387.07M CNY |
| Interest income | 22.65M CNY | 25.25M CNY | 24.13M CNY | 16.55M CNY | 15.35M CNY |
| Interest expense | 14.38M CNY | 15.36M CNY | 10.7M CNY | 10.29M CNY | 7.98M CNY |
| Depreciation and amortization | 30.34M CNY | 36.43M CNY | 39.03M CNY | 38.64M CNY | 36.98M CNY |
| Operating income | 302.79M CNY | 388.73M CNY | 349.49M CNY | 356.9M CNY | 190.66M CNY |
| Net income | 251.2M CNY | 318.63M CNY | 250.16M CNY | 281.22M CNY | 187.64M CNY |
Company facts updated Sep 15, 2026.
Recent quarterly results
Recent quarterly results
Cash distributions grouped by calendar year; partial years are marked.
HK$0.50
2025 complete year+733.3% since 2021
2026 partial: HK$0.34
HK$0.06
2,021
HK$0.18
2,022
HK$0.36
2,023
HK$0.60
2,024
HK$0.50
2,025
HK$0.34
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jun 16, 2026 | HK$0.34Annual | Jun 17, 2026 | Jun 26, 2026 |
Dividend | Jun 16, 2025 | HK$0.50Annual | Jun 17, 2025 | Jun 26, 2025 |
Dividend | Jun 14, 2024 | HK$0.60Annual | Jun 17, 2024 | Jun 26, 2024 |
Dividend | Jun 16, 2023 | HK$0.36Annual | Jun 19, 2023 | Jun 30, 2023 |
Dividend | May 25, 2022 | HK$0.18Annual | May 26, 2022 | Jun 13, 2022 |
Dividend | Jun 16, 2021 | HK$0.06Annual | Jun 17, 2021 | Jun 30, 2021 |
Ex-dividend Jun 16, 2026
HK$0.34
Annual
Record Jun 17, 2026 · Payment Jun 26, 2026
Ex-dividend Jun 16, 2025
HK$0.50
Annual
Record Jun 17, 2025 · Payment Jun 26, 2025
Ex-dividend Jun 14, 2024
HK$0.60
Annual
Record Jun 17, 2024 · Payment Jun 26, 2024
Ex-dividend Jun 16, 2023
HK$0.36
Annual
Record Jun 19, 2023 · Payment Jun 30, 2023
Ex-dividend May 25, 2022
HK$0.18
Annual
Record May 26, 2022 · Payment Jun 13, 2022
Ex-dividend Jun 16, 2021
HK$0.06
Annual
Record Jun 17, 2021 · Payment Jun 30, 2021
Funds reporting this stock among their holdings, ordered by reported position size.
Dimensional - Emerging Markets Core Equity 2 ETFDFEM
Dimensional World ex U.S. Core Equity 2 ETFDFAX
Dimensional Emerging Markets Sustainability Core 1 ETFDFSEAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
